LOI Deadline
Posted: 3/19/2024

ADDF-Harrington Scholar Program

The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute. This is a special funding opportunity separate from ADDF’s Therapeutic Funding Programs.

NOTE Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).


  • Required Letter of Intent: June 3, 2024, 5:00 PM EDT
  • Invited Full Proposal: August 26, 2024, 5:00 PM EDT
Areas of Interest

The 2024 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:

  • Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance)
  • Senescence (including cells that have halted division, shifted towards a secretory phenotype, altered morphology and epigenetics, and decreased apoptosis)
Eligibility Requirements
  • Academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada and United Kingdom only are eligible to apply.
  • Lead investigator must have an MD, a PhD, or equivalent.
  • Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, slow, or reverse Alzheimer’s disease or related dementias (vascular dementia, frontotemporal dementia, Lewy Body dementia, LATE etc).
  • Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity.
  • Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are strongly encouraged to apply.
Amount Description

The award typically entails up to $600,000 over 2 years with dedicated support for milestone-driven projects from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.

Funding Type
LOI Deadline:
Sponsor: Rolling